Lexaria Bioscience Corp (NASDAQ: LEXX) is a worldwide innovator for drug delivery platforms. The company recently announced that its pharmacokinetics and tolerability VIRAL-A20-3 study is done, and it achieved positive results. The study showed how DehydraTECH was able to enable colchicine, one of the many drugs Lexaria has tested with SARS-CoV-2, to benefit from the company’s proprietary processing and formulation, which resulted in increased delivery.
This colchicine component is an approved therapeutic treatment that has anti-inflammatory effects principally used in gout treatment and other conditions like cardiac inflammation. It’s also incredibly effective at mitigating cytokine storms linked with COVID 19/SARS-CoV-2. Colchicine is sometimes used and recommended as a treatment for emergent pericarditis in kids. This is in scenarios where this kind of cardiac inflammation arises because of an mRNA COVID-19 vaccination administration.
Like the many other antiviral components that the company has managed to process with DehydraTECH (for example, ebastine, remdesivir’s nucleoside analog GS-44152, efavirenz, and darunavir), oral colchicine currently exhibits a diminished bio-availability in human beings. Although, Lexaria Bioscience believes it can get better efficacy and safety outcomes. Oral colchicine today displays a bio-availability of around 45%
Colchicine also has a narrow therapeutic index. This means that the difference between non-toxic and toxic doses is marginal, to say the least, and there’s a possibility of significant advantages in allowing for a reduced dosage while you maintain therapeutic delivery levels. The company hopes to better colchicine’s bio-availability to a sufficient level that it could allow for reduced dosages.
About the VIRAL-A20-3 study
VIRAL-A20-3 was done using Sprague-Dawley rats. Twenty were given oral gavage doses using either controlled colchicine formulations or DehydraTECH itself. The study analyzed peak concentrations as well as the drug deliveries into the bloodstream of the rats. VIRAL was done by a premier, independent animal testing lab situated in the US.
The study also looks at how Lexaria’s two other untested antiviral drugs were being absorbed. The bloodstream delivery results were outstanding with these two other drugs. With that said, there is still a lot of work that needs to be done on these two other drugs.